Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Americas Gold and Silver Corporation Common Shares no par value (USAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Americas Gold and Silver Corporation Common Shares no par value — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Americas Gold and Silver Corporation Common Shares no par value trades at $3.76 (market cap $1.36B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 5.5× Americas Gold and Silver Corporation Common Shares no par value's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Americas Gold and Silver Corporation Common Shares no par value nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Americas Gold and Silver Corporation Common Shares no par value for 0 Days on average.
| SYRE | USAS | |
|---|---|---|
Market Cap | $7.52B | $1.36B |
Volume | 1,441,031 | 3,177,621 |
Sector | Health | Basic Materials |
52-Week High | $108.92 | $10.03 |
52-Week Low | $22.18 | $3.59 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $6.52B | $1.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
USAS trades at $4.02, down 4.29% on the day, reflecting ongoing volatility amid mixed operational performance. The company reported a net loss of $87.45M in 2025, though revenue is projected to grow to $182M in 2026 with a narrowing loss. Recent news highlights progress at its Galena and Cosalá mines, including high-grade silver discoveries and sustainability initiatives, signaling potential for future production growth.
The outlook is speculative, with high-risk turnaround potential driven by operational improvements and exposure to silver and critical minerals. Key risks include persistent negative profitability, high valuation multiples like EV/EBITDA of 455.68, and reliance on successful mine development. Analyst consensus is unanimously bullish, but investors must weigh execution risks against long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Americas Gold and Silver Corporation Common Shares no par value
Americas Gold and Silver Corporation is a Canada-based mining company that explores for and produces silver, along with by-product gold, copper, lead, and zinc. Its operating assets include the Galena Complex in Idaho and the Cosalá Operations in Sinaloa, Mexico.
Read more on USAS →
